Robert R. Ruffolo
"Dr. Robert R. Ruffolo is a distinguished scientist with number of global recognitions for his executive leadership in the Pharmaceutical industry. He was appointed to the Board of Directors of GVK BIO in April 2019.
Dr. Ruffolo served as the President of R&D and Senior Vice President of Wyeth Pharmaceuticals (now, Pfizer) from 2002 to 2008. Prior to Wyeth, Bob was Senior Vice President in R&D at SmithKline Beecham Pharmaceuticals (now GSK) for 17 years. Bob played a significant role in the discovery and/or development of a number of marketed products, including carvedilol, ropinerole, dobutamine, and eprosartan, among others. He has been recognised with several prestigious awards, including the Discoverer’s Award in 2008, for his pioneering work on the discovery of carvedilol for the treatment of congestive heart failure. Bob currently serves as a Director at Sigilon Therapeutics, Elucida Oncology, Sapience Therapeutics and Aridis Pharmaceuticals. He is also the President of Ruffolo Consulting LLC, a position he has held since 2008."